Genmab A/S (GMAB)
NASDAQ: GMAB · IEX Real-Time Price · USD
27.75
+0.51 (1.87%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Genmab Revenue
Genmab had revenue of $2.57B in the twelve months ending March 31, 2024, with 15.36% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $599.57M with 44.50% year-over-year growth. In the year 2023, Genmab had annual revenue of $2.44B with 16.77% growth.
Revenue (ttm)
$2.57B
Revenue Growth
+15.36%
P/S Ratio
7.03
Revenue / Employee
$1,166,344
Employees
2,204
Market Cap
18.08B USD
Revenue Chart
* The company reports in DKK currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.44B | 350.53M | 16.77% |
Dec 31, 2022 | 2.09B | 814.75M | 63.89% |
Dec 31, 2021 | 1.28B | -382.24M | -23.06% |
Dec 31, 2020 | 1.66B | 856.65M | 106.96% |
Dec 31, 2019 | 800.90M | 336.94M | 72.62% |
Dec 31, 2018 | 463.96M | 82.65M | 21.68% |
Dec 31, 2017 | 381.30M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Teva Pharmaceutical | 16.00B |
Baxter International | 14.89B |
Labcorp Holdings | 12.30B |
Illumina | 4.49B |
Hologic | 3.96B |
Align Technology | 3.92B |
The Cooper Companies | 3.73B |
BioNTech SE | 2.97B |
GMAB News
- 5 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewsWire
- 24 days ago - Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma - Business Wire
- 24 days ago - Completion of Share Buy-back Program - GlobeNewsWire
- 25 days ago - EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) - Business Wire
- 27 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 4 weeks ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 5 weeks ago - Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewsWire
- 5 weeks ago - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - GlobeNewsWire